Day 1 – Thursday, 5 May 2022

08:45-09:00  Registration
09:00-09:10  Welcome and introduction

Session 1: Pharmacology of asthma and COPD - current knowledge
Chairs: Dave Singh and Joergen Vestbo

09:10-09:30  Understanding the mechanism of action of bronchodilators in asthma and COPD (Maria Gabriella Matera – IT)
09:30-09:40  Discussion
09:40-10:00  How do inhaled steroids work and interact in asthma and COPD? (Maarten Van Den Berge – NL)
10:00-10:10  Discussion
10:10-10:30  Biomarker guided pharmacological intervention (Daiana Stolz – CH/DE)
10:30-10:40  Discussion
10:40-11:00  Coffee break

Session 2: Emerging new concepts and treatments
Chairs: Mario Cazzola and Daiana Stolz

11:00-11:20  Do we understand remodelling in asthma and COPD? (Eleni Papakonstantinou – CH/DE)
11:20-11:30  Discussion
11:30-11:50  Lung regeneration: is it still far from reality? (Reinoud Gosens – NL)
11:50-12:00  Discussion
12:00-12:20  Emerging classes of drugs for the treatment of obstructive lung disease (Dave Singh - UK)
12:20-12:30  Discussion
12:30-13:30  Lunch

Session 3: Challenges for clinical development
Chairs: Clive Page and Maria Gabriella Matera

13:30-14:00  Key challenges faced for approval of anti-inflammatory drugs for asthma and COPD – European Medicines Agency perspective (Laura Fregonese – UK) - remotely
14:00-14:30  General discussion

14:30-15:25  Session 4 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD? – Dave Singh, Paola Rogliani and Alexander Mathioudakis
14:30-14:40  Explain tasks and operating methods
14:40-15:25  Session 1 - Identifying surrogate markers and outcomes
•  Group 1:  Which surrogate markers can be used to assess and quantify disease in a pre-clinical stage? Do we need drug intervention in pre-clinical detectable disease? – Chair: Dave Singh
•  Group 2:  Which are the read-outs to assess drug effect in the progression of the disease? – Chair: Paola Rogliani
•  Group 3:  Is an effect on remodelling required for drug efficacy? If so, how to assess it? – Alexander Mathioudakis
15:25-15:45  Coffee break
15:45-16:30  Session 2 - How do we select treatments for patients with severe asthma and COPD?
  •  **Group 1:** What is non-clinical evidence to sustain combination therapy including ICS in COPD? What about LABA/LAMA in asthma? – **Chair:** Dave Singh
  •  **Group 2:** Are there realistic treatment goals for monoclonal antibodies in COPD? How do they differ from asthma? – **Chair:** Paola Rogliani
  •  **Group 3:** Which features suggest considering patients for non-pharmacological, i.e. bronchoscopic interventions in asthma and COPD? – **Alexander Mathioudakis**

16:30-17:00  **Round table**

Day 2 – Friday, 6 May 2022

09:00-09:30  Summary of day 1 and possible output, next steps and plenary discussion

**Session 5: Challenges in the treatment of patient with asthma and COPD**

**Chairs:** Maarten Van Den Berge and Clive Page

09:30-09:50  New insights into steroid resistance (*Nicola Hanania – USA*) – *pre-recorded*
09:50-10:00  Discussion
10:00-10:20  Comorbidities and drug interactions (*Mario Cazzola – IT*)
10:20-10:30  Discussion
10:30-10:50  Precision medicine in asthma, pharmacogenomics and beyond (*Anke-Hilse Maitland- Van Der Zee – NL*)
10:50-11:00  Discussion
11:00-11:20  General discussion

11:20-11:40  **Coffee break**

11:40-12:20  Session 6 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD? – Joergen Vestbo, Reinoud Gosens, Maia Rukhadze

11:40-11:50  Explain tasks and operating methods
11:50-12:20  **Session 1 - How to streamline clinical and basic research**
  •  **Group 1:** How can academia and industry cooperate in translating relevant clinical questions to experiments? – **Chair:** Joergen Vestbo
  •  **Group 2:** How to translate experimental data to clinical practice? – **Chair:** Reinoud Gosens
  •  **Group 3:** Which themes should be prioritized? – **Chair:** Maia Rukhadze

12:20-12:50  **Round table**

12:50-13:00  Conclusion

13:00-14:00  **Lunch and Departure**